1. Home
  2. ENTX vs SQNS Comparison

ENTX vs SQNS Comparison

Compare ENTX & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • SQNS
  • Stock Information
  • Founded
  • ENTX 2010
  • SQNS 2003
  • Country
  • ENTX Israel
  • SQNS France
  • Employees
  • ENTX N/A
  • SQNS N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • SQNS Semiconductors
  • Sector
  • ENTX Health Care
  • SQNS Technology
  • Exchange
  • ENTX Nasdaq
  • SQNS Nasdaq
  • Market Cap
  • ENTX 90.2M
  • SQNS 85.7M
  • IPO Year
  • ENTX 2018
  • SQNS 2011
  • Fundamental
  • Price
  • ENTX $2.43
  • SQNS $2.63
  • Analyst Decision
  • ENTX Strong Buy
  • SQNS Strong Buy
  • Analyst Count
  • ENTX 1
  • SQNS 1
  • Target Price
  • ENTX $10.00
  • SQNS $7.50
  • AVG Volume (30 Days)
  • ENTX 83.2K
  • SQNS 121.8K
  • Earning Date
  • ENTX 03-07-2025
  • SQNS 02-11-2025
  • Dividend Yield
  • ENTX N/A
  • SQNS N/A
  • EPS Growth
  • ENTX N/A
  • SQNS N/A
  • EPS
  • ENTX N/A
  • SQNS 2.00
  • Revenue
  • ENTX $99,000.00
  • SQNS $36,762,000.00
  • Revenue This Year
  • ENTX N/A
  • SQNS $10.14
  • Revenue Next Year
  • ENTX N/A
  • SQNS $8.54
  • P/E Ratio
  • ENTX N/A
  • SQNS $1.32
  • Revenue Growth
  • ENTX 607.14
  • SQNS 9.36
  • 52 Week Low
  • ENTX $0.95
  • SQNS $0.85
  • 52 Week High
  • ENTX $3.35
  • SQNS $7.18
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 54.06
  • SQNS 37.45
  • Support Level
  • ENTX $2.21
  • SQNS $2.47
  • Resistance Level
  • ENTX $2.62
  • SQNS $3.39
  • Average True Range (ATR)
  • ENTX 0.21
  • SQNS 0.22
  • MACD
  • ENTX -0.01
  • SQNS -0.08
  • Stochastic Oscillator
  • ENTX 69.35
  • SQNS 17.39

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

Share on Social Networks: